US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks

As U.S. markets respond positively to recent developments in tariffs and corporate earnings, investors are exploring various opportunities across the financial landscape. Penny stocks, often associated with smaller or newer companies, provide a unique opportunity for growth at lower price points. Despite being considered a niche investment area today, these stocks can still offer significant potential when backed by strong financial health and fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8577	$6.52M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$121.59M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2799	$9.75M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$3.03	$88.27M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.43	$47.85M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$3.09	$51.01M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.35	$21.99M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9234	$83.69M	★★★★★☆
SideChannel (OTCPK:SDCH)	$0.038815	$9.04M	★★★★★★

Click here to see the full list of 707 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Gevo (NasdaqCM:GEVO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Gevo, Inc. operates as a carbon abatement company with a market cap of $404.57 million.

Operations: The company generates revenue from two segments: Gevo, with $0.96 million, and Renewable Natural Gas, contributing $14.63 million.

Market Cap: $404.57M

Gevo, Inc., a carbon abatement company, is navigating the penny stock landscape with notable developments. Despite being pre-revenue in its Gevo segment and unprofitable overall, it has a market cap of US$404.57 million and generates US$14.63 million from Renewable Natural Gas. The company's management and board are experienced, with average tenures of 3.3 and 6.3 years respectively, while debt levels have decreased over five years to a debt-to-equity ratio of 13.3%. Recent collaborations include extending an agreement with LG Chem for commercializing its Ethanol-to-Olefins technology targeting sustainable fuels and chemicals markets.

• Unlock comprehensive insights into our analysis of Gevo stock in this financial health report.
• Learn about Gevo's future growth trajectory here.

Sagimet Biosciences (NasdaqGM:SGMT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing fatty acid synthase (FASN) inhibitors for treating diseases caused by dysfunctional metabolic pathways in the United States, with a market cap of approximately $150.03 million.

Operations: Sagimet Biosciences Inc. does not have any reported revenue segments.

Market Cap: $150.03M

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, is navigating the penny stock sector with its focus on developing FASN inhibitors. The company remains pre-revenue, with no significant revenue streams and a market cap of US$150.03 million. Despite being debt-free and having short-term assets of US$157.2 million exceeding liabilities of US$4.1 million, it is unprofitable with losses widening over recent years. Recent presentations highlighted promising Phase 2b data for its lead candidate, denifanstat, showing potential benefits in treating fibrosis and cardiovascular conditions, yet profitability remains elusive in the near term as earnings are forecast to decline by 18.7% annually over three years.

• Click here to discover the nuances of Sagimet Biosciences with our detailed analytical financial health report.
• Understand Sagimet Biosciences' earnings outlook by examining our growth report.

3D Systems (NYSE:DDD)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: 3D Systems Corporation offers 3D printing and digital manufacturing solutions across various regions including the Americas, Europe, the Middle East, North Africa, the Asia Pacific, and Oceania with a market cap of approximately $507.22 million.

Operations: The company's revenue is derived from two primary segments: Healthcare, contributing $200.56 million, and Industrial, accounting for $243.39 million.

Market Cap: $507.22M

3D Systems, with a market cap of US$507.22 million, is navigating challenges in the penny stock space. The company faces significant financial hurdles, reporting a net loss of US$178.63 million for Q3 2024 and impairment charges totaling US$143.7 million. Despite these setbacks, 3D Systems maintains sufficient cash runway for over three years and has formed strategic partnerships like the one with Daimler Buses to enhance service capabilities through remote spare part printing solutions. While currently unprofitable and experiencing high share price volatility, its experienced management team is steering efforts towards innovation in additive manufacturing technologies.

• Get an in-depth perspective on 3D Systems' performance by reading our balance sheet health report here.
• Evaluate 3D Systems' prospects by accessing our earnings growth report.

Turning Ideas Into Actions

• Explore the 707 names from our US Penny Stocks screener here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com